Skip to main content
SpringerLink
Log in

Palliative Chemotherapie: Standard und Individualisierung des Magen- und Kardiakarzinoms

  • Chapter
  • First Online:
Moderne Chirurgie des Magen- und Kardiakarzinoms

  • 1636 Accesses

Zusammenfassung

Bei dem überwiegenden Anteil der Patienten mit Magenkarzinom wird die Erkrankung erst in einem Stadium diagnostiziert, in dem eine kurative Operation nicht mehr in Frage kommt. Solchen Patienten sollte man eine palliative Chemotherapie mit dem Ziel anbieten, das Leben zu verlängern und tumorbedingte Symptome aufzuschieben oder zu verbessern.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 84.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Al-Batran SE, Hartmann JT, Hofheinz R et al. (2008) Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 19(11): 882–887

    Article  Google Scholar 

  • Al-Batran SE, Hartmann JT, Probst S et al. (2008) Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26(9): 1435–1442

    Article  CAS  PubMed  Google Scholar 

  • Bang YJ, Van Cutsem E, Feyereislova A et al. (2010) ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 376(9742): 687–697

    Article  CAS  PubMed  Google Scholar 

  • Cunningham D, Starling N, Rao S et al. (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36–46

    Article  CAS  PubMed  Google Scholar 

  • Cunningham D, Tebbutt NC, Davidenko I et al. (2015) Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol 33 (Suppl; Abstr 4000)

    Article  Google Scholar 

  • Dragovich T1, McCoy S, Fenoglio-Preiser CM et al. (2006) Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol Oct 24(30): 4922–4927

    Article  CAS  Google Scholar 

  • Ford HE, Marshall A, Bridgewater JA, et al. (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014 15(1): 78–86. doi: 10.1016/S1470-2045(13)70549-7

    Article  CAS  Google Scholar 

  • Fuchs CS, Tomasek J, Yong CJ, Dumitru F et al. (2014) REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383(9911): 31–39. doi: 10.1016/S0140-6736(13)61719-5

    Article  CAS  PubMed  Google Scholar 

  • Hecht JR, Bang YJ, Qin S et al. (2013) Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGIC Trial. J Clin Oncol 31 (Suppl; Abstr LBA4001)

    Google Scholar 

  • Hironaka S, Ueda S, Yasui H et al. (2013) Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31(35): 4438–4444

    Article  CAS  PubMed  Google Scholar 

  • Hofheinz R, Susanna Hegewisch-Becker S, Thuss-Patience PC et al. (2014) HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group. J Clin Oncol 32: 5s (Suppl; Abstr 4073)

    Google Scholar 

  • Iveson T, Donehower RC, Davidenko I et al. (2014) Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol. 15(9): 1007–1018. doi: 10.1016/S1470-2045(14)70023-3

    Article  CAS  PubMed  Google Scholar 

  • Kang YK, Kang WK, Shin DB et al. (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20(4): 666–673

    Article  PubMed  Google Scholar 

  • Kang Y, Ohtsu A, Van Cutsem E et al. (2010) AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 28: 7s (Suppl; Abstr LBA4007); http://abstract.asco.org/AbstView_74_52720.html

    Article  Google Scholar 

  • Kang JH, Lee SI, Lim do H et al. (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30(13): 1513–1518

    Article  CAS  PubMed  Google Scholar 

  • Kang YK, Shah MA, Ohtsu A, Van Cutsem E et al. (2016) A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). J Clin Oncol 34 (Suppl 4S) abstr 5

    Article  Google Scholar 

  • Koizumi W, Narahara H, Hara Tet al. (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3): 215–221

    Article  CAS  PubMed  Google Scholar 

  • Lordick F, Kang YK, Chung HC et al. (2013) Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.Lancet Oncol 14(6): 490–499. doi: 10.1016/S1470-2045(13)70102-5

    Article  CAS  PubMed  Google Scholar 

  • Lorenzen S, Hentrich M, Haberl C et al. (2007) Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 18(10): 1673–1679

    Article  CAS  PubMed  Google Scholar 

  • Moehler M, Al-Batran SE, Andus T et al. (2011) German S3-guideline: Diagnosis and treatment of esophagogastric cancer.Z Gastroenterol 49(4): 461–531. doi: 10.1055/s-0031-1273201

    Article  CAS  PubMed  Google Scholar 

  • Muro K, Bang YJ, Shankaran V et al. (2015) Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. J Clin Oncol 33 (Suppl 3; Abstr 3)

    Article  Google Scholar 

  • Ohtsu A, Shah MA, Van Cutsem E et al. (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29(30): 3968–3976. doi: 10.1200/JCO.2011.36.2236

    Article  CAS  PubMed  Google Scholar 

  • Ohtsu A, Ajani JA, Bai YX et al. (2013) Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 31(31): 3935–3943. doi: 10.1200/JCO.2012.48.3552

    Article  CAS  PubMed  Google Scholar 

  • Qin S (2014) Phase III study of apatinib in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 32: 5s (Suppl; Abstr 4003)

    Google Scholar 

  • Satoh T, Xu RH, Chung HC et al. (2014) Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN–a randomized, phase III study. J Clin Oncol 32(19): 2039–49. doi: 10.1200/JCO.2013.53.6136

    Article  CAS  PubMed  Google Scholar 

  • Shah MA, Janjigian YY, Stoller R et al. (2015a) Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. J Clin Oncol 33: 3874–3879

    Article  CAS  PubMed  Google Scholar 

  • Shah MA, Bang YJ, Lordick F et al. (2015b) METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC). Clin Oncol 33 (Suppl; Abstr 4012)

    Google Scholar 

  • Thuss-Patience P (2015) Personalisierte Tumormedizin. In: Medizin Forschung, Exzellenzforschung in der Medizin. Institut für wissenschaftliche Veröffentlichungen, 7, ISSN 2191–9003

    Google Scholar 

  • Thuss-Patience PC, Kretzschmar A, Bichev D et al. (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47(15): 2306–2314

    Article  CAS  PubMed  Google Scholar 

  • Thuss-Patience PC, Al-Batran SE, Siveke JT et al. (2015) Pazopanib and 5-FU/oxaliplatin as first-line treatment in advanced gastric cancer: PaFLO, a randomized phase II study from the AIO (Arbeitsgemeinschaft Internistische Onkologie). J Clin Oncol 33 (Suppl; Abstr 4033)

    Google Scholar 

  • Van Cutsem E, Moiseyenko VM, Tjulandin S et al. (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991–4997

    Google Scholar 

  • Van Cutsem E, Kang Y, Chung H et al. (2009) Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27: 18s (Suppl; Abstr LBA4509)

    Article  Google Scholar 

  • Van Cutsem E, de Haas S, Kang YK et al. (2012) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 30(17): 2119–2127. doi: 10.1200/JCO.2011.39.9824

    Article  CAS  PubMed  Google Scholar 

  • Waddell T, Chau I, Cunningham D et al. (2013) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 14(6): 481–489. doi: 10.1016/S1470-2045(13)70096-2. Erratum: Lancet Oncol 2013 Jun; 14(7):e254

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wagner AD, Grothe W, Haerting J et al. (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903–2909

    Article  CAS  PubMed  Google Scholar 

  • Wilke H, Muro K, Van Cutsem E et al. (2014) RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15(11): 1224–1235. doi: 10.1016/S1470-2045(14)70420-6

    Article  CAS  PubMed  Google Scholar 

  • Xu DZ, Geng QR, Tian Y et al. (2010) Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer. BMC Cancer 10: 536. doi: 10.1186/1471-2407-10-536

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie, Charité Universitätsmedizin Berlin Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Deutschland

    P. Thuss-Patience

Authors
  1. P. Thuss-Patience
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Charité Universitätsmedizin Berlin, Berlin, Berlin, Germany

    Martin E. Kreis

  2. Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Charité Universitätsmedizin Berliin, Berlin, Berlin, Germany

    Hendrik Seeliger

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag GmbH Deutschland

About this chapter

Cite this chapter

Thuss-Patience, P. (2017). Palliative Chemotherapie: Standard und Individualisierung des Magen- und Kardiakarzinoms. In: Kreis, M., Seeliger, H. (eds) Moderne Chirurgie des Magen- und Kardiakarzinoms. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-53188-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-53188-4_8

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-53187-7

  • Online ISBN: 978-3-662-53188-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation